Limits...
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB - Br. J. Cancer (2002)

Bottom Line: The only effective treatments reported to date relied on hepatic arterial chemoembolisation or -perfusion.Although objective responses were more frequent within the cohort receiving intraarterial fotemustine (21.7 vs 8%), this difference did not translate into a significant benefit in overall survival, i.e., 369 and 349 days, respectively.Of note, this overall survival is much longer than that repeatedly reported for stage IV uveal melanoma not treated with fotemustine, suggesting a therapeutic activity of this cytostatic drug even after systemic administration.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, University of Würzburg, Germany. becker-jc.derma@mail.uni-wuerzburg.de

Show MeSH

Related in: MedlinePlus

Treatment schedule.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376169&req=5

fig1: Treatment schedule.

Mentions: A vignette of the treatment protocol is shown in Figure 1Figure 1


Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB - Br. J. Cancer (2002)

Treatment schedule.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376169&req=5

fig1: Treatment schedule.
Mentions: A vignette of the treatment protocol is shown in Figure 1Figure 1

Bottom Line: The only effective treatments reported to date relied on hepatic arterial chemoembolisation or -perfusion.Although objective responses were more frequent within the cohort receiving intraarterial fotemustine (21.7 vs 8%), this difference did not translate into a significant benefit in overall survival, i.e., 369 and 349 days, respectively.Of note, this overall survival is much longer than that repeatedly reported for stage IV uveal melanoma not treated with fotemustine, suggesting a therapeutic activity of this cytostatic drug even after systemic administration.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, University of Würzburg, Germany. becker-jc.derma@mail.uni-wuerzburg.de

Show MeSH
Related in: MedlinePlus